Showing 911-920 of 3315 results for "".
EMPOWER - Cornea Health Diagnostic Tools
https://modernod.com/podcasts/the-mod-pod/empower-cornea-health-diagnostic-tools/39861/In the fourth podcast episode, Jacob Lang, OD, FAAO, leads a discussion on functional vision testing, workflow integration, and real-world cases with Paul Hammond, OD, and Jason Compton, OD, FAAO, that demonstrates how advanced diagnostics improve outcomes and strengthen patient trust. The panel alsFirst Commerical Surgeries Performed with MacTel Therapy
https://modernod.com/podcasts/eyewire-news-the-podcast/first-commerical-surgeries-performed-with-mactel-therapy/37097/Charles Wykoff, MD, PhD, shares his experience performing the first commercial case for a patient with MacTel; VSY Biotechnology launches its Enova Hydrophobic IOLs with a new preloaded delivery system; and an app is launched that syncs AI directly to leading OCT devices. Learn more about your ad chTryptyr Now Available in US
https://modernod.com/podcasts/eyewire-news-the-podcast/tryptyr-now-available-in-us/37095/Alcon launches its recently approved dry eye drug Tryptyr; a potential $1 billion deal is made to advance extended-release therapies for eye diseases; and two companies with late-stage AMD drug candidates complete phase 3 enrollment. Learn more about your ad choices. Visit megaphone.fm/adchoicesGlaukos' MIGS Technology Certified in Europe; New Phase 3 Data for Presbyopia Drop
https://modernod.com/podcasts/eyewire-news-the-podcast/glaukos-migs-technology-certified-in-europe-new-phase-3-data-for-presbyopia-drop/37091/Glaukos receives European Union certification for several of its MIGS technologies; Opus Genetics and Viatris present phase 3 results for their investigational presbyopia eye drop; and J&J launches the first and only daily disposable contact lens for people with both astigmatism and presbyopia.Alcon Gains FDA Approval for Novel DED Drug
https://modernod.com/podcasts/eyewire-news-the-podcast/alcon-gains-fda-approval-for-novel-ded-drug/37087/Alcon receives FDA approval for a novel pharmaceutical treatment for dry eye disease; Genentech’s Susvimo ocular implant is approval for a third indication in the US; and the makers of two investigational treatments for wet AMD complete enrollment in their respective phase 3 trials. Learn more abSpecial Report: Executives Discuss Overcoming Challenges
https://modernod.com/podcasts/eyewire-news-the-podcast/special-report-executives-discuss-overcoming-challenges/37086/Ophthalmology executives share challenging situations they encountered, as well as the steps needed to overcome the challenge. Learn more about your ad choices. Visit megaphone.fm/adchoices90. Focus Shift: From IOLs to LALs ft. Dr. Marcella Labelle
https://modernod.com/podcasts/four-eyes/90-focus-shift-from-iols-to-lals-ft-dr-marcella-labelle/37040/In this episode of Four Eyes, we sit down with Dr. Marcella LaBelle, an optometrist in Alberta with over 20 years of experience in refractive surgical care, to dive into the world of intraocular and light-adjustable lenses. From identifying ideal candidates (even those without cataracts) to demystifUtilizing AI to Provide DR Screening to Underserved Communities
https://modernod.com/podcasts/eyewire-news-the-podcast/utilizing-ai-to-provide-dr-screening-to-underserved-communities/37079/EyewireTV speaks with the leaders of Digital Diagnostics and AEYE Health about their diabetic screening technology, racial and socioeconomic disparities in eye care, and their mission to improve health equity by expanding their technology into underserved populations. Learn more about your ad choiceAlcon Launches PanOptix Pro in US
https://modernod.com/podcasts/eyewire-news-the-podcast/alcon-launches-panoptix-pro-in-us/37078/Alcon introduces its next-generation trifocal IOL; Alcon announces a deal to advance its clinical-stage allogeneic cell therapy; and Bausch + Lomb announces a voluntary recall of IOLs on its enVista platform. Learn more about your ad choices. Visit megaphone.fm/adchoicesFDA Approves First Treatment for MacTel
https://modernod.com/podcasts/eyewire-news-the-podcast/fda-approves-first-treatment-for-mactel/37075/The CEO of Neurotech joins us to talk about the FDA approval of the first treatment for MacTel; a target action date is set for Sydnexis’ pediatric myopia treatment candidate; and three eye care companies collaborate to launch a wearable vision testing platform. Learn more about your ad choices. Vis